HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Clinical characteristics and outcomes of benign, atypical, and malignant breast adenomyoepithelioma: a single institution's experience.

AbstractBACKGROUND:
Breast adenomyoepithelioma (AME) is rare. We sought to evaluate clinical characteristics, treatment, and outcomes of a contemporary patient cohort stratified by histology.
METHODS:
We queried health records containing "adenomyoepithelioma" between 2000 and 2018. Histology was confirmed with centralized review and classified into benign, atypical, and malignant. Clinical characteristics, demographics, treatment, and oncologic outcomes were compared.
RESULTS:
Our query yielded 24 patients with adenomyoethelioma. Histologic diagnosis was confirmed in 12 (benign n = 6, atypical n = 3, malignant n = 3). Excision (n = 11) was the usual initial treatment, with margin status available in 10 patients. Mean follow up was 44 months (range 1-138 months) with no local recurrence observed. Two patients with benign AME presented with concurrent contralateral breast cancer, and one with malignant AME died of metastatic AME.
CONCLUSION:
Wide excision of atypical and malignant AME is recommended as local recurrence when excised completely was not observed. Given metastatic potential of malignant AME, multimodal therapy may be warranted.
AuthorsNaomi Wiens, Daniel I Hoffman, Cassie Ye Huang, Anupma Nayak, Julia Tchou
JournalAmerican journal of surgery (Am J Surg) Vol. 219 Issue 4 Pg. 651-654 (04 2020) ISSN: 1879-1883 [Electronic] United States
PMID30982573 (Publication Type: Journal Article)
CopyrightCopyright © 2019. Published by Elsevier Inc.
Topics
  • Adenomyoepithelioma (pathology, therapy)
  • Adult
  • Aged
  • Aged, 80 and over
  • Biopsy
  • Breast Neoplasms (pathology, therapy)
  • Carcinoma, Ductal, Breast (pathology, therapy)
  • Female
  • Follow-Up Studies
  • Humans
  • Mastectomy
  • Mastectomy, Segmental
  • Middle Aged
  • Neoplasms, Multiple Primary (pathology, therapy)
  • Radiotherapy, Adjuvant

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: